'Deep phenotyping': Characterizing populations in the era of genomics and systems biology

Current Opinion in Lipidology

Volumn 19, Issue 2, 2008, Pages 151-157

  Tracy, Russell P ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Genomics; Phenotyping

Indexed keywords

GENETIC VARIABILITY; GENOMICS; LIFESPAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SYSTEMS BIOLOGY;

GENOMICS; HUMANS; PHENOTYPE; SYSTEMS BIOLOGY;

EID: 41649090385     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f73893     Document Type: Review

References (45)

1. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002; 298:2345-2349.
2. Petretto E, Liu ET, Aitman TJ. A gene harvest revealing the archeology and complexity of human disease. Nat Genet 2007; 39:1299-1301. The report of the July 2007 Hinxton Conference demonstrating an 'inflexion point' in human genotype-phenotype studies.
3. Schechter B. Deep computing overview: daring to think deep. Yorktown Heights, New York, USA: IBM Research; 2007. http://domino.research.ibm.-com/ comm/wwwr_thinkresearch.nsf/pages/computing299.html. [Accessed 28 January 2008.]
4. Swope W. Deep computing for the life sciences. IBM Systems J 2001; 40:248-262.
5. Snow J. On the mode of communication of cholera. London: John Churchill; 1855.
6. Schulte P. A conceptual and historical framework for molecular epidemiology. In: Schulte P, Perera F, editors. Molecular epidemiology: principles and practices. San Diego, CA: Academic Press; 1993. pp. 3-44.
7. O'Leary D, Polak J, Wolfson S, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke 1991; 22:1155-1163.
8. Humphries S. DNA polymorphisms of the apolipoprotein genes: their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. Atherosclerosis 1988; 72:89-108.
9. Lussier YA, Liu Y. Computational approaches to phenotyping: high-throughput phenomics. Proc Am Thorac Soc 2007; 4:18-25. This review lays out a conceptual framework for large-scale, high-throughput phenomics studies.
10. Zerhouni EA. Clinical research at a crossroads: the NIH roadmap. J Investig Med 2006; 54:171-173.
11. Keir SL, Wardlaw JM, Warlow CP. Stroke epidemiology studies have underestimated the frequency of intracerebral haemorrhage. A systematic review of imaging in epidemiological studies. J Neurol 2002; 249:1226-1231.
12. Collins FS. The case for a US prospective cohort study of genes and environment. Nature 2004; 429:475-477.
13. Ives D, Fitzpatrick A, Bild D, et al. Surveillance and ascertainment of cardiovascular events. Ann Epidemiol 1995; 5:278-285.
14. Raser JM, O'Shea EK. Noise in gene expression: origins, consequences, and control. Science 2005; 309:2010-2013.
15. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106:388-391.
16. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999; 149:261-267.
17. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376.
18. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasmalevels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22:2066-2071.
19. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int JObes Relat Metab Disord 2003; 27 (Suppl 3):S29-34.
20. Burke AP, Farb A, Pestaner J, et al. Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. Circulation 2002; 105:419-424.
21. Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36:108-117.
22. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44:62-69.
23. Lanpher B, Brunetti-Pierri N, Lee B. Inborn errors of metabolism: the flux from Mendelian to complex diseases. Nat Rev Genet 2006; 7:449-460. This is an excellent review of the state-of-the art in the field of the genetics of inborn errors of metabolism, and the work needed to move from these penetrant disorders to the smaller but cummulative impact of genes in complex chronic diseases.
24. Rader DJ. Illuminating HDL: is it still a viable therapeutic target? N Engl J Med 2007; 357:2180-2183. This editorial is a critical review of the surprising failure of the cholesteryl ester transfer protein inhibitor torcetrapib, and lays out some of the reasons why this may have occurred.
25. Wagenknecht L, Mayer E, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS): objectives, design and recruitment results. Ann Epidemiol 1995; 5:464-472.
26. Rathmann W, Haastert B, Icks A, et al. Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol 2007; 22:439-445.
27. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
28. McMahan CA, Gidding SS, Malcom GT, et al. Comparison of coronary heart disease risk factors in autopsied young adults from the PDAY Study with living young adults from the CARDIA study. Cardiovasc Pathol 2007; 16:151-158.
29. Wright D, Poller L, Thomson JM, et al. A longitudinal study of the factor VII rise during pregnancy. Thromb Haemost 1998; 79:328-330.
30. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145:237-246. This is an important paper reporting the association of failing renal function with cardiovascular disease.
31. Psaty BM, Furberg CD, Kuller LH, et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch Intern Med 1999; 159:1339-1347.
32. Patel DA, Srinivasan SR, Xu JH, et al. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 2007; 56:792-798.
33. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77:64-77.
34. Walston JD, Fallin MD, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet 2007; 122:485-494.
35. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972-978.
36. Gattone M, Iacoviello L, Colombo M, et al. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. Am Heart J 2001; 142:633-640.
37. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152:897-907.
38. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.
39. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 1985; 153:9-13.
40. Thakore AH, Guo CY, Larson MG, et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol 2007; 99:1598-1602.
41. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in c-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103:1191-1193.
42. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48:396-401.
43. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89:2728-2735.
44. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100:717-722.
45. Jenny NS, Yanez ND, Psaty BM, et al. Inflammation biomarkers and near-term death in older men. Am J Epidemiol 2007; 165:684-695. This study is the first to document the powerful effect of group inflammation markers in the prediction of fatal events in the elderly. The relative risks of almost 20 suggest important clinical benefit if replicated.